Literature DB >> 1887676

High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA.

A Sjölander1, K Lövgren, S Ståhl, L Aslund, M Hansson, P A Nygren, M Larsson, M Hagstedt, B Wåhlin, K Berzins.   

Abstract

Immunostimulating complexes (ISCOMs) are spherical structures where immunogens are presented as multimers in a matrix of the adjuvant Quil A. ISCOMs have been shown to enhance the immunogenicity of several antigens important to both human and veterinary vaccine development. We have coupled a fusion protein, designated ZZ-M2, comprising eight copies of the C-terminal repeat subunit EENV of the Plasmodium falciparum blood-stage antigen Pf155/RESA and two IgG-binding domains of staphylococcal protein A (SpA), to preformed influenza virus envelope protein ISCOMs. Rabbits immunized with the conjugated ISCOMs produced high titres of antibodies even after the first injection. These antibodies reacted with the EENV repeat sequence in ELISA and with Pf155/RESA in immunofluorescence on infected erythrocytes. The antibody response, which was sustained for more than 20 weeks, was efficiently boosted and superior or equal to that obtained after immunization with ZZ-M2 in Freund's complete adjuvant. In contrast, the antibody response induced in rabbits immunized with ZZ-M2 in Syntex Adjuvant Formulation-MF (SAF-MF) was weak and of short duration. The antibodies produced after immunization with ZZ-M2 coupled to influenza virus ISCOMs mainly recognized epitopes formed by two or more EENV subunits and were highly specific for Pf155/RESA. Furthermore, the antibodies efficiently inhibited merozoite reinvasion of erythrocytes in vitro, indicating that they recognized epitopes exposed on the native antigen. In addition, the ZZ-M2-conjugated ISCOMs also induced high titres of antibodies reacting with SpA or the influenza virus envelope protein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887676     DOI: 10.1016/0264-410x(91)90133-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  New age adjuvants and delivery systems for subunit vaccines.

Authors:  S Kurella; M Manocha; L Sabhnani; B Thomas; D N Rao
Journal:  Indian J Clin Biochem       Date:  2000-08

2.  Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes.

Authors:  A Lundén; K Lövgren; A Uggla; F G Araujo
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

3.  Antibodies to a non-repeat region of Plasmodium falciparum antigen Pf155/RESA in individuals from malaria-endemic areas.

Authors:  A B Siddique; N Ahlborg; M Warsame; P Perlmann; K Berzins
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

Review 4.  Vaccination of adults against travel-related infectious diseases, and new developments in vaccines.

Authors:  P C Döller
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

Review 5.  The Use of Synthetic Carriers in Malaria Vaccine Design.

Authors:  Liam Powles; Sue D Xiang; Cordelia Selomulya; Magdalena Plebanski
Journal:  Vaccines (Basel)       Date:  2015-10-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.